HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposi…
Author: Business Wire
iVeena Awarded $2 Million National Eye Institute Grant to Advance Novel Therapy for Pediatric Myopia
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company, today announced it has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute …
Lumata Health Expands Leadership Bench with New Chief Technology Officer and Chief Growth Officer
RALEIGH, N.C.–(BUSINESS WIRE)– #digitalhealth–Lumata Health, the company focused on ending preventable blindness with continuous ophthalmic care for people facing chronic eye disease, today announced two new executive hires to propel the company int…
Lumata Health Expands Leadership Bench with New Chief Technology Officer and Chief Growth Officer
RALEIGH, N.C.–(BUSINESS WIRE)– #digitalhealth–Lumata Health, the company focused on ending preventable blindness with continuous ophthalmic care for people facing chronic eye disease, today announced two new executive hires to propel the company int…
Character Biosciences Expands Leadership Team with Key Appointments and Announces Series B Extension
JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, today announced the expansion of its leadership team with four senior appointments, including Robert Kim, M.D….
Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy
FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the…
Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy
FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the…
New Public Service Campaign Encourages Eye Exams to Save Sight
CLARKSBURG, Md.–(BUSINESS WIRE)– #StopAMD–BrightFocus Foundation launches two national public service announcements encouraging eye exams to save sight from macular degeneration and glaucoma.
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $HIND–Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for tre…
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $HIND–Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for tre…
Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced its launch with an initial $100…
Le Symposium 2025 sur les nouvelles technologies de la vision périphérique rétinienne et la première conférence clinico-universitaire VPR se sont conclus avec un grand succès.
PÉKIN–(BUSINESS WIRE)–Le 3 septembre 2025, le « Symposium 2025 sur les nouvelles technologies de la vision périphérique rétinienne et la première conférence d’échange clinico-universitaire sur la VPR » s’est tenu à Hangzhou Chine. Organisé par Beijin…
2025 New Technology Symposium on Retinal Peripheral Vision and the First VPR Clinical Academic Exchange Conference Concluded Successfully
BEIJING–(BUSINESS WIRE)–On September 3, 2025, the “2025 New Technology Symposium on Retinal Peripheral Vision and the First VPR Clinical Academic Exchange Conference” was held in Hangzhou, hosted by Chinese Association of Pathophysiology and Ophthalm…
iCare Launches ALTIUS: The Game-Changing Cloud Platform Redefining Eye Care Imaging
RALEIGH, N.C.–(BUSINESS WIRE)–iCare USA, a global innovator in eye care diagnostics, proudly unveils the launch of iCare ALTIUS™, a sleek cloud platform that’s set to disrupt how eye care professionals capture, manage, and share diagnostic images. Bu…
PPG launches PPG HI-GARD Non-Methanol hard coating for ophthalmic lenses
PITTSBURGH–(BUSINESS WIRE)–PPG (NYSE:PPG) today announced the launch of PPG HI-GARD® Non-Methanol hard coating for 1.5 standard index ophthalmic lenses. Developed as a drop-in replacement for traditional methanol-based coatings, the new formulation e…
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy s…
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
GENEVA–(BUSINESS WIRE)–Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollment…
North America Intraocular Lens Market Trends and Forecast Report 2025-2033 | Ageing Population, Cataract Cases, and Premium Lens Demand Drive Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Intraocular Lens Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The North America Intraocular Lens Market is expected…
Inflammasome Therapeutics’ K8 Implant Cuts Lesion Growth by more than 50% in Geographic Atrophy after Three Months in Multi-Center Trial
NEWTON, Mass.–(BUSINESS WIRE)– #NRTIs–Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ophthalmic and neurological conditions. Today, the…